Session Information
Session Type: Abstract Submissions (ACR)
Background/Purpose: Delays in patient presentation to primary care providers, subsequent referral for rheumatology assessment, and recognition of rheumatoid arthritis (RA) by the rheumatologist increase time to diagnosis. This time period is a modifiable determinant of joint damage and affects the odds of entering remission, and factors impacting this time must be elicited. Our aim was to evaluate whether time to diagnosis is influenced by measures of disease severity or a family history of RA, sociodemographic factors affecting access to care (age, sex, socioeconomic status [SES], education level, ethnicity), or comorbidities that may influence the physical examination, such as obesity, mental health conditions, or other musculoskeletal pain conditions.
Methods: A prospective national cohort of patients with confirmed or possible RA by 2010 ACR criteria (n=1,151) was evaluated for predictors of the duration of time to diagnosis. Variables examined in univariate analysis are summarized in Table 1. Simple linear regression was applied to each variable, and significant predictors carried forward to multivariate linear regression.
Results:
TABLE 1. Variables Assessed in Univariate Analysis for Time to Diagnosis |
|
Female |
74% |
Age, mean (SD) |
54 (14.7) years |
Caucasian ethnicity |
83% |
BMI, mean (SD) |
28.6 (10.5) |
DAS28, mean (SD) |
5.02 (1.44) |
Swollen joint count, mean (SD) |
28 Joints: 7.7 (6.0); 66 Joints: 9.8 (7.9) |
Tender joint count, mean (SD) |
28 Joints: 8.3 (6.5); 66 Joints: 12.7 (9.4) |
HAQ, mean (SD) |
1.02 (0.70) |
Patient Global (VAS 0-10), mean (SD) |
5.7 (2.9) |
Acute Phase Reactants, mean (SD) |
ESR: 28.1 (22.6) mm/hr; CRP: 14.4 (17.8) mg/L |
Serology |
Rheumatoid factor positive 67%; Anti-CCP positive 58% |
Education |
Only elementary or high school 46%; College or post-secondary 51% |
Annual Income |
<$20,000: 12%; $20,000-$50,000: 24%; $50,000-$100,000: 18%; >$100,000: 8% |
Mental Health Condition |
Depression: 11%; Other: 1% |
Fibromyalgia |
2% |
Osteoarthritis |
11% |
Family History of RA |
22% |
The mean symptom duration at the baseline rheumatology visit was 6.0 months (range 0.1-19.6). In univariate analysis, age, joint counts, DAS28, patient global, HAQ, ESR, CRP, education level and anti-CCP status were all significant predictors (p<0.05) for time to diagnosis, whereas BMI, sex, ethnicity, income, RF status, family history of RA, and history of depression, fibromyalgia or osteoarthritis had no effect. In multivariate analysis, higher swollen joint counts, higher ESR, worse patient global scores, and negative anti-CCP antibody status were significant predictors of shorter time to diagnosis (Table 2).
TABLE 2. Multivariate Analysis for Predictors of Time to Diagnosis |
|||
Parameter |
Estimate |
95% CI |
P-value |
Intercept |
7.789 |
7.257; 8.322 |
<.0001 |
Swollen Joints |
-0.051 |
-0.089; -0.013 |
0.0085 |
ESR |
-0.016 |
-0.026; -0.006 |
0.0017 |
Patient Global Score |
-0.085 |
-0.161; -0.009 |
0.0280 |
Damaged joint count |
-0.090 |
-0.204; 0.023 |
0.1192 |
Anti-CCP Positive |
0.814 |
0.383; 1.245 |
0.0002 |
Conclusion: Recognition of RA is not affected by a family history, sociodemographic factors, body habitus, mental health conditions, or other musculoskeletal pain syndromes. Worse patient global, more swollen joints, higher ESR and anti-CCP status influence time to diagnosis. The impact of fewer swollen joints and normal laboratory parameters on delay to diagnosis merits further consideration.
Disclosure:
C. Barnabe,
UCB, Pfizer, Amgen, Roche, Janssen BMS, ,
5;
J. Xiong,
None;
G. Boire,
None;
C. A. Hitchon,
None;
B. Haraoui,
None;
J. E. Pope,
None;
J. C. Thorne,
None;
E. Keystone,
Abbott Laboratories Amgen Inc, AstraZeneca Pharamceuticals LP, Bristol-Myers Squibb, Centocor Inc, F. Hoffmann-LaRoche Inc, Genzyme, Merck, Novartis Pharmaceuticals, Pfizer Pharmaceuticals, UCB,
2,
Abbott Laboratories, AstraZeneca Pharma, Biotest, Bristol-Myers Squibb, Centocor Inc, F. Hoffman-LaRoche Inc, Genentech Inc, Merck, Nycomed, Pfizer Pharmaceuticals, UCB, Amgen, Janssen Inc,
5;
D. Tin,
None;
V. P. Bykerk,
Amgen, Pfizer, Roche, BMS, UCB, Janssen Biotech and Abbott,
2;
« Back to 2012 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/disease-activity-and-anti-ccp-status-but-not-sociodemographic-factors-or-patient-comorbidities-affect-time-to-diagnosis-in-early-rheumatoid-arthritis/